

10/542724

JC12 Rec'd PCT/PTC 20 JUL 2005

Q89067

12-14-2005



103136735

MODIFIED Form PTO-1595
(Rev. 10/02)

SHEET

U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

To the Director of the U.S. Patent and Trademark Office: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

Tohru KAMBE Takayuki MARUYAMA
Toru MARUYAMA Kiyoto SAKATA
Kaoru KOBAYASHI Hideyuki YOSHIDA
Kousuke TANI Shinsei FUJIMURA
Yoshihiko NAKAI Akio NISHURA
Toshihiko NAGASE Nobutaka ABE

2. Name and address of receiving party(ies):

ONO PHARMACEUTICAL CO., LTD.
1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi,
OSAKA 541-8526 JAPAN

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No

3. Nature of conveyance:

☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other

Execution Date: June 28, 2005, June 30, 2005, and May 29, 2005

Additional name(s) & address(es) attached? ☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: June 28, 2005, June 30, 2005, and May 29, 2005

A. Patent Application No.(s)
Not Yet Assigned

B. Patent No.(s)
Unknown

Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

SUGHRUE MION, PLLC
WASHINGTON OFFICE
23373
CUSTOMER NUMBER

6. Total number of applications and patents involved:

1

7. Total fee (37 CFR 3.41): \$40.00

☒ Enclosed.☐ Authorized to be charged to Deposit Account No. 19-4880.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

8. Deposit Account Number:

19-4880

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Mark Boland

Reg. No. 32,197

July 20, 2005

Date

Total number of pages including cover sheet, attachments, and documents: 6

Mail documents to be recorded with required cover sheet information to:

MAIL STOP ASSIGNMENT RECORDATION SERVICES

Director of the U.S. Patent and Trademark Office

P.O. Box 1450

Alexandria, VA 22313-1450

07/26/2005 LLANDGRA 00000056 10542724

04 FC:8021

40.00 DP

PATENT
REEL: 017330 FRAME: 0272

ASSIGNMENT

Whereas, I/we Tohru KAMBE, Toru MARUYAMA, Kaoru KOBAYASHI,
Kousuke TANI and Yoshihiko NAKAI, all of Osaka, Japan

hereinafter called assignor(s), have invented certain improvements in

8-AZAPROSTAGRANDIN DERIVATIVES AND MEDICAL USE THEREOF

and executed an application for Letters Patent of the United States of America therefor on

June 28, 2005 ; and

Whereas, ONO PHARMACEUTICAL CO., LTD. of
1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, OSAKA 541-8526 JAPAN

(assignee), desires to acquire the entire right, title and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. § 119, and I/we request the Director – U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request my/our attorneys SUGHRUE MION, PLLC of 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3213 to insert here in parentheses (Application number _____, filed _____) the filing date and application number of said application when known.

Date: s/ _____

Date: s/ _____

Date: June 28, 2005 s/ Kaoru Kobayashi

Date: s/ _____

Date: s/ _____

ASSIGNMENT

Whereas, I/we Tohru KAMBE, Toru MARUYAMA, Kaoru KOBAYASHI,
Kousuke TANI and Yoshihiko NAKAI, all of Osaka, Japan

hereinafter called assignor(s), have invented certain improvements in

8-AZAPROSTAGRANDIN DERIVATIVES AND MEDICAL USE THEREOF

and executed an application for Letters Patent of the United States of America therefor on

June 30, 2005 ; and

Whereas, ONO PHARMACEUTICAL CO., LTD. of
1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, OSAKA 541-8526 JAPAN

(assignee), desires to acquire the entire right, title and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. § 119, and I/we request the Director – U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request my/our attorneys SUGHRUE MION, PLLC of 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3213 to insert here in parentheses (Application number _____, filed _____) the filing date and application number of said application when known.

Date: June 30, 2005

s/ Tohru Kambe

Date: June 30, 2005

s/ Toru Maruyama

Date:

s/ _____

Date:

s/ _____

Date: June 30, 2005

s/ Yoshihiko Nakai

ASSIGNMENT

Whereas, I/we Toshihiko NAGASE, Takayuki MARUYAMA, Kiyoto SAKATA, Hideyuki YOSHIDA, Shinsei FUJIMURA, Akio NISHIURA and Nobutaka ABE, all of Osaka, Japan

hereinafter called assignor(s), have invented certain improvements in

8-AZAPROSTAGRAN DIN DERIVATIVES AND MEDICAL USE THEREOF
and executed an application for Letters Patent of the United States of America therefor on

June 30, 2005 ; and

Whereas, ONO PHARMACEUTICAL CO., LTD. of
1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, OSAKA 541-8526 JAPAN

(assignee), desires to acquire the entire right, title and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. § 119, and I/we request the Director – U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request my/our attorneys SUGHRUE MION, PLLC of 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3213 to insert here in parentheses (Application number _____, filed _____) the filing date and application number of said application when known.

Date: June 30, 2005

s/ Toshihiko Nagase

Date: June 30, 2005

s/ Takayuki Maruyama

Date: June 30, 2005

s/ Kiyoto Sakata

Date:

s/ _____

Date: June 30, 2005

s/ Shinsei Fujimura

Date: June 30, 2005

s/ Akio Nishiura

Date: June 30, 2005

s/ Nobutaka Abe

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

PATENT
REEL: 017330 FRAME: 0275

ASSIGNMENT

Whereas, I/we Tohru KAMBE, Toru MARUYAMA, Kaoru KOBAYASHI,
Kousuke TANI and Yoshihiko NAKAI, all of Osaka, Japan

hereinafter called assignor(s), have invented certain improvements in

8-AZAPROSTAGRAN DIN DERIVATIVES AND MEDICAL USE THEREOF
and executed an application for Letters Patent of the United States of America therefor on

May 29, 2005 ; and

Whereas, ONO PHARMACEUTICAL CO., LTD. of
1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, OSAKA 541-8526 JAPAN

(assignee), desires to acquire the entire right, title and interest in the application and invention, and to
any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named
assignee, its successors and assigns, the entire right, title and interest in the application and the
invention disclosed therein for the United States of America, including the right to claim priority under
35 U.S.C. § 119, and I/we request the Director – U.S. Patent and Trademark Office to issue any
Letters Patent granted upon the invention set forth in the application to the assignee, its successors
and assigns; and I/we will execute without further consideration all papers deemed necessary by the
assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request my/our attorneys SUGHRUE MION, PLLC of 2100
Pennsylvania Avenue, N.W., Washington, D.C. 20037-3213 to insert here in parentheses
(Application number _____, filed _____) the filing date and
application number of said application when known.

Date: s/ _____

Date: s/ _____

Date: s/ _____

Date: May 29, 2005 s/ Kousuke Tani

Date: s/ _____

ASSIGNMENT

Whereas, I/we Toshihiko NAGASE, Takayuki MARUYAMA, Kiyoto SAKATA, Hideyuki YOSHIDA, Shinsei FUJIMURA, Akio NISHIURA and Nobutaka ABE, all of Osaka, Japan

hereinafter called assignor(s), have invented certain improvements in

8-AZAPROSTAGRAN DIN DERIVATIVES AND MEDICAL USE THEREOF

and executed an application for Letters Patent of the United States of America therefor on

May 29, 2005 ; and

Whereas, ONO PHARMACEUTICAL CO., LTD. of
1-5, Doshomachi 2-chome, Chuo-ku, Osaka-shi, OSAKA 541-8526 JAPAN

(assignee), desires to acquire the entire right, title and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. § 119, and I/we request the Director – U.S. Patent and Trademark Office to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request my/our attorneys SUGHRUE MION, PLLC of 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3213 to insert here in parentheses (Application number _____, filed _____) the filing date and application number of said application when known.

Date: s/ _____

Date: s/ _____

Date: s/ _____

Date: May 29, 2005 s/ Hideyuki Yoshida

Date: s/ _____

Date: s/ _____

Date: s/ _____

(Legalization not required for recording but is prima facie evidence of execution under 35 U.S.C. §261)

RECORDED: 07/20/2005

PATENT
REEL: 017330 FRAME: 0277